Literature DB >> 3689669

Halothane hepatitis in an animal model: time course of hepatic damage.

K M Knights1, G K Gourlay, P D Hall, J F Adams, M J Cousins.   

Abstract

The present study extends previous reports of hepatic damage 24 h after halothane anaesthesia in the phenobarbitone pretreated hypoxic rat model by fully characterizing the lesion during the time course of its onset and recovery. Phenobarbitone treated animals exposed to halothane (1% for 2 h in 14% inspired oxygen) were killed 1, 2, 4, 6, 12 and 24 h and 2, 3, 5, 10, 15 and 30 days after commencement of the anaesthetic period. Blood was collected 1 day before the administration of halothane and at the time of killing for determination of serum alanine aminotransferase (ALT), a biochemical index of hepatic damage. Liver tissue was obtained immediately at post-mortem for histological examination. Serum ALT was increased at the end of the anaesthetic period, i.e. 2 h, with peak levels occurring at 12-24 h and remaining elevated for 3 days after exposure. Minor changes in liver histology were evident at 2 h in 50% of the animals and by 6 h all animals had mild hepatic injury. The extent of the necrosis was maximal at 24 h and this was sustained until 3 days. By 5 days after exposure minimal evidence of liver damage was observed and animals killed at 30 days had morphologically normal livers. Elevation of serum ALT or changes in liver histology were not observed in other treatment groups. The early onset of damage at 2-6 h is in keeping with direct hepatotoxicity associated with the biotransformation of halothane.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3689669      PMCID: PMC2013189     

Source DB:  PubMed          Journal:  Br J Exp Pathol        ISSN: 0007-1021


  15 in total

1.  Antibodies against the mitochondrial fraction of liver after toxic liver damage in rats.

Authors:  R N Pinckard; D M Weir
Journal:  Clin Exp Immunol       Date:  1966-01       Impact factor: 4.330

2.  Hepatic necrosis associated with halothane anesthesia.

Authors:  R L Peters; H A Edmondson; T B Reynolds; J C Meister; T J Curpey
Journal:  Am J Med       Date:  1969-11       Impact factor: 4.965

3.  Factors influencing halothane hepatotoxicity in the rat hypoxic model.

Authors:  R C Jee; I G Sipes; A J Gandolfi; B R Brown
Journal:  Toxicol Appl Pharmacol       Date:  1980-02       Impact factor: 4.219

4.  Hepatic necrosis caused by halothane and hypoxia in phenobarbital-treated rats.

Authors:  W T Ross; B P Daggy; R R Cardell
Journal:  Anesthesiology       Date:  1979-10       Impact factor: 7.892

5.  Changes in rat hepatic microsomal mixed function oxidase activity following exposure to halothane under various oxygen concentrations.

Authors:  K M Knights; G K Gourlay; M J Cousins
Journal:  Biochem Pharmacol       Date:  1987-03-15       Impact factor: 5.858

6.  An animal model of halothane hepatotoxicity: roles of enzyme induction and hypoxia.

Authors:  G E McLain; I G Sipes; B R Brown
Journal:  Anesthesiology       Date:  1979-10       Impact factor: 7.892

7.  Time-course of formation of volatile reductive metabolites of halothane in humans and an animal model.

Authors:  G K Gourlay; J F Adams; M J Cousins; J H Sharp
Journal:  Br J Anaesth       Date:  1980-03       Impact factor: 9.166

8.  A prospective study of liver enzyme and other changes following repeat administration of halothane and enflurane.

Authors:  J P Fee; G W Black; J W Dundee; P D McIlroy; H M Johnston; S B Johnston; I H Black; H G McNeill; D W Neill; J R Doggart; J D Merrett; J R McDonald; D S Bradley; M Haire; S A McMillan
Journal:  Br J Anaesth       Date:  1979-12       Impact factor: 9.166

9.  Sensitisation to halothane-altered liver components in severe hepatic necrosis after halothane anaesthesia.

Authors:  D Vergani; D Tsantoulas; A L Eddleston; M Davis; R Williams
Journal:  Lancet       Date:  1978-10-14       Impact factor: 79.321

10.  Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis.

Authors:  D Vergani; G Mieli-Vergani; A Alberti; J Neuberger; A L Eddleston; M Davis; R Williams
Journal:  N Engl J Med       Date:  1980-07-10       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.